Program Goals The Importance of Controlling Nausea and Vomiting in the Setting of Chemotherapy CINV Consequences Emetogenicity of IV Chemotherapy Emetogenicity of Oral Chemotherapy Types of CINV ID: 633240
Download Presentation The PPT/PDF document "Pioneering the Future: Innovations and ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Pioneering the Future: Innovations and Strategies for Preventing Chemotherapy-Induced Nausea and VomitingSlide2
Program GoalsSlide3
The Importance of Controlling Nausea and Vomiting in the Setting of ChemotherapySlide4
CINV: ConsequencesSlide5
Emetogenicity of IV ChemotherapySlide6
Emetogenicity of Oral ChemotherapySlide7
Types of CINVSlide8
Neurotransmitters Involved in EmesisSlide9
Major Classes of Antiemetic Agents: DefinitionsSlide10
Pharmacokinetic and Physiological Differences Among 5-HT3 RAsSlide11
CINV Clinical Practice GuidelinesRecommendations and Related EvidenceSlide12
HEC: Guideline Recommendations Slide13Slide14
Olanzapine + PALO + DEX vs APR + PALO + DEX: EfficacySlide15
Olanzapine + PALO + DEX vs APR + PALO + DEX: SafetySlide16
MEC: Guideline Recommendations Slide17
PALO + DEX vs GRN + DEX in Chemotherapy-Naive Patients Receiving Cisplatin (≥ 50 mg/m2) or AC-Based ChemotherapySlide18
Gaps/Goals: MEC and HEC SettingsSlide19
Should DEX be Administered on Days 1-3 or Day 1 Only When Given in Combination With PALO?Slide20
Assessing the Efficacy of Single-dose DEX in Chemotherapy-Naive Patients Receiving AC-Based ChemotherapySlide21Slide22
Steroid Sparing in Non-AC MEC: EfficacySlide23
Steroid Sparing in Non-AC MEC: Treatment-Related AEsSlide24
Emerging Treatments for Preventing CINVSlide25
5-HT3 RAsSlide26
NK-1 RAs: Available FormulationsSlide27
Investigational NK-1 RAsSlide28
Phase 2 Trial: Rolapitant (200 mg oral) + OND + DEX in Chemotherapy-Naive Patients Receiving HECSlide29
Oral NEPA + Oral DEX vs Oral PALO + Oral DEX in AC-Based MEC: Multinational, Randomized, Double-Blind Phase 3 StudySlide30
NEPA + DEX vs PALO + DEX in AC-Based MEC: Efficacy OutcomesSlide31
NEPA + DEX vs PALO + DEX in AC-Based MEC: SafetySlide32
NEPA: Phase 2 Netupitant Dose-Finding StudyStudy DesignSlide33
NEPA: Phase 2 Netupitant Dose-Finding StudyOverall CR RatesSlide34
NEPA: Phase 2 TrialSecondary Efficacy EndpointsSlide35
NEPA in Multicycle MEC and HEC: Multicenter, Randomized, Double-blind, Phase 3 StudySlide36
NEPA in Multicycle MEC and HEC: Overall CR RatesSlide37
NEPA in Multicycle MEC and HEC: Most Common AEsSlide38
Innovations and Strategies in the Prevention of CINV: SummarySlide39
AbbreviationsSlide40
Abbreviations (cont)Slide41
ReferencesSlide42
References (cont)Slide43
References (cont)Slide44
References (cont)Slide45
References (cont)Slide46
References (cont)Slide47
References (cont)Slide48
References (cont)Slide49
References (cont)